☰

Captor Therapeutics

From discovery to first-in-human on data that holds up

Industry
Pharmaceutical — Targeted Protein Degradation
Headquarters
Wrocław, Poland
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Captor Therapeutics's published strategy and is not endorsed by, or produced in cooperation with, Captor Therapeutics. Company website

Strategic priorities

Captor Therapeutics is mid-transition from a discovery-stage targeted protein degradation company to a clinical-stage one. Two lead assets, CT-01 (a GSPT1 degrader for hepatocellular carcinoma, Phase I initiated) and CT-03 (an MCL-1 degrader for blood cancers, IND-enabling), are the operational focus for the 2023–2025 strategic plan. The capital plan describes a runway into Q3 2025 funded by a PLN 40M equity raise and a PLN 52M Medical Research Agency grant, with first-in-human readouts of CT-01 positioned as the principal valuation inflection.

Capability is built around Optigrade, a proprietary discovery platform that uses molecular glues and bifunctional degraders to address targets considered undruggable by traditional inhibitors. Captor's published scientific position is that degrading roughly 70 percent of MCL-1 is sufficient for efficacy, against the much higher target coverage typical of MCL-1 inhibitors, a claim the company frames as a path to a wider therapeutic window. The platform has already produced one disclosed discovery partnership with Ono Pharmaceutical and additional undisclosed US-based partnerships.

The production footprint is a 1,100 m² laboratory in Wrocław housing proteomics, bioprocess and chemistry teams, supported by a proteomics lab established in 2022. GLP regulatory toxicology studies in rats and crab-eating macaques (CT-01, reported 2023) and an appointed global CRO are the most recent named steps in the path to clinical supply. The published 2023 R&D spend was PLN 77.1M, against total available funding of PLN 129.8M.

Everything in the clinical plan rests on data Captor's reviewers and regulators can replay: proteomics and bioprocess output from a mixed-vendor instrument fleet, IND-enabling study documentation, and quality records that need to satisfy both the EMA and the FDA. The most concrete digital work to do is turn the present instrument and lab data into that replayable chain, and keep it that way as the company moves toward a US listing.

Challenges we see

  • Manufacturing Operations

    Building clinical supply under a CMC timeline

    The transition from laboratory-scale discovery to Phase I clinical trials requires escalation in Chemistry, Manufacturing, and Controls (CMC): Good Manufacturing Practice (GMP) manufacture of drug substance and development of final drug product, including capsules for CT-01. The company describes scale-up of the CT-01 drug substance (CPT-6281) as already underway and ongoing GMP product development as on the critical path.

    Where several CMC activities run in parallel against a fixed clinical-start date, the timeline is governed less by the science than by the orderly integration of GMP batch data, stability results and dose-form development.

  • Regulatory Compliance

    Producing IND/CTA evidence for a novel mechanism

    Obtaining an Investigational New Drug (IND) clearance from the FDA or a Clinical Trial Application (CTA) approval from the EMA is the named requirement for both CT-01 and CT-03. For CT-01, GLP toxicology studies in rats and crab-eating macaques were completed in 2023. Targeted protein degradation involves ternary complex formation and E3 ligase recruitment that regulators are still learning to evaluate.

    Where the mechanism is new to reviewers, the documentation that meets the bar is the documentation that explains the biology in a queryable form, so toxicology, pharmacokinetic and mechanism-of-action evidence has to be assembled as data rather than as a finished narrative.

  • R&D Manufacturing

    Demonstrating selectivity for MCL-1 ahead of the clinic

    Captor is positioning CT-03 as a degrader of MCL-1 in hematological malignancies, an area where earlier small-molecule MCL-1 inhibitors have largely been stopped for cardiac safety reasons. The company points to roughly 70 percent MCL-1 protein degradation as the operating range it intends to demonstrate in crab-eating macaques and early clinical dose-escalation.

    Where selectivity and the therapeutic window are demonstrated rather than assumed, the readouts that establish them — troponin data, target engagement, downstream pharmacology — have to come from instruments the company can interrogate after the fact.

  • Portfolio Management Operations

    Making capital last across the lead programs

    Total available funding at the end of 2023 stood at PLN 129.8M (PLN 75.7M cash and equivalents plus PLN 54.1M in grants), against PLN 77.1M of R&D spend. The capital narrative accompanying the strategic plan extends the runway into Q3 2025. Within that envelope, the company discontinued the CT-04 colorectal cancer project in late 2023.

    Where one budget covers multiple programmes, deciding what runs in parallel and what pauses is itself a data problem — the case for each choice has to be drawn from the same proteomics, pharmacology and development records that the rest of the company uses.

  • Digital Transformation Integration

    Connecting the proteomics and bioprocess instrument fleet

    Captor runs a proteomics laboratory, a bioprocess capability and chemistry teams across roughly 1,100 m² of laboratory space, drawing on more than 30 instruments including bioreactors, chromatography systems and analytical balances from multiple vendors. The 2022 establishment of the proteomics laboratory is described as essential to current and future projects.

    Where instrument output is reconciled by hand across teams, the same assay gets repeated and the same number gets entered twice; instrument-level capture with a shared reading protocol removes both, which is what clinical supply, IND documentation and external partner reporting all depend on.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Putting trial readouts on instrument-derived data

    CT-01 has begun Phase I, and CT-03 is approaching an IND filing. The pharmacokinetic, pharmacodynamic and safety readouts for both will be reviewed by an Independent Data Monitoring Committee and submitted to the EMA and the FDA, so the underlying numbers need to be retraceable to the instrument that produced them. Today's flow captures instrument output in different formats and reconciles it by hand.

    Connecting the bench instruments to a monitored data flow lets safety, PK and PD readouts be presented with their lineage intact, which is the format in which a dose-escalation decision or an IND module actually has to be argued.

    • Captor Strategy Next Steps 2023–2025, presentation, 2023
    • Captor 2023 Results and Update, April 2024

  2. Modelling ternary complexes before they are made

    Designing molecular glues and bifunctional degraders for GSPT1 and the NEK7 programme means iterating on three-dimensional target-ligase-degrader arrangements. Each candidate is currently evaluated by synthesis and bench assay, with lead-optimisation timing and wet-lab cost set by that loop.

    A simulation layer that represents ternary complex formation, ligase recruitment and ubiquitination kinetics in silico lets Captor's scientists narrow the candidate pool before committing to synthesis, and turns each round of design into a reusable model asset rather than a one-off experiment.

    • Captor TPD Summit presentation, 2023
    • Captor Strategy Next Steps 2023–2025, presentation, 2023

  3. Unifying the instrument fleet across a 1,100 m² lab

    The 30-or-so instruments that produce Captor's daily data — bioreactors, chromatography, analytical balances, plate readers, imaging — come from multiple vendors and span generations. Half of the scientific team holds PhDs, and a meaningful share of their time goes into recording instrument output by hand.

    Pulling these instruments onto a common data backbone with documented protocols lets research time go back to design and interpretation, and gives every downstream report — partnership deliverables, IND modules, internal reviews — a single source.

    • Captor 2022 Annual Report, 2023
    • Captor About us, accessed 2026

  4. Standing up GMP control software for clinical-scale manufacture

    CMC for CT-01 and the forthcoming supply for CT-03 both run against an FDA and EMA acceptability bar. Captor's published position is that ongoing GMP product development is on the critical path of the CT-01 program, which means batch consistency, process control and the underlying electronic records have to satisfy inspection in their own right.

    Putting clinical-stage control software, batch records and electronic signatures in place before CMC volume scales makes each GMP batch auditable on its own data and avoids retrofitting validation into a line that is already running patient-facing supply.

    • Captor 2023 Results and Update, April 2024
    • Captor Strategy Next Steps 2023–2025, presentation, 2023

  5. Lifting the daily data load off bench scientists

    Specialised scientific time at Captor is concentrated on data entry, file reconciliation and report assembly — manual flow cytometry counts, instrument readings copied across systems, IND-enabling summaries drafted from raw records. The same work is concentrated in a small group of PhD scientists in a market where their availability is itself a constraint.

    Narrow agents and automation that take the repetitive part of this work off the bench — drafting document summaries from controlled records, checking completeness against a template, flagging outliers across data sets — leave the scientists for interpretation, with a named reviewer signing each output.

    • Captor 2023 Results and Update, April 2024
    • Captor Sustainability Report, accessed 2026

What we'd propose

  • Digital Lab

    A monitored data flow for CT-01 and CT-03 trial readouts

    We connect the instruments that produce the CT-01 and CT-03 readouts — bioreactors, plate readers, balances, imaging systems — so pharmacokinetic, pharmacodynamic and safety numbers reach the trial record with instrument identity, method version and timestamp attached, and so the Independent Data Monitoring Committee and regulators can trace each figure back to its source.

    • Instrument capture and integration

      Numbers from the bench, with lineage

      Integrate the bench instruments that produce the CT-01 and CT-03 readouts using OPC UA (Open Platform Communications Unified Architecture) and MQTT, capturing temperature, pH, plate counts and balances with instrument identity, method version and timestamp attached instead of transcribed by hand.

    • Trial-grade data pipeline

      Readouts as data, not as paperwork

      Stream instrument output into a monitored pipeline so the run sheet that the Independent Data Monitoring Committee sees is built from the same source as the report filed to the agency, with an audit trail preserving the chain of custody.

    • GxP-grade visualisation for the review room

      A single view on dose-escalation data

      Provide GxP-compliant dashboards so pharmacokinetic and pharmacodynamic curves, dose-level decisions and adverse-event context are presented from one dataset, available to clinical, regulatory and partner audiences without rebuilding reports per request.

    • Dose-escalation decisions sit on numbers with traceable instrument lineage, not on figures re-keyed between systems.
    • The data set submitted to EMA and FDA is the same data set the IDMC sees, which keeps review and inspection on one record.
    • IND modules are assembled from system-of-record evidence rather than reconstructed for the regulator.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    A simulation layer for ternary complex design

    A cloud-agnostic simulation platform that represents ternary complex formation, ligase recruitment and ubiquitination kinetics, so GSPT1, MCL-1 and NEK7 candidate degraders are narrowed in silico before they are committed to synthesis.

    • TPD simulation engine

      Modelling degrader-E3 ligase-target complexes

      Build a representation of ternary complex formation and the kinetics of E3 ligase recruitment, so scientists can run candidate degrader-E3 ligase combinations against the in-house structural models and keep the simulation as a reusable scientific asset.

    • No-code analytics for bio-engineers

      Simulation results usable by the bench scientist

      Expose simulation results through a no-code analytics layer so Captor's bio-engineers can examine outputs, set runs and decide which candidates progress without commissioning custom data work for each design round.

    • Process know-how as an asset

      Each cycle compounds

      Capture every simulation round and its outcome as structured data so the Optigrade platform's own design history becomes part of what is offered to partners like Ono Pharmaceutical, increasing the asset value of the platform itself.

    • Wet-lab rounds shrink because candidate narrowing moves upstream into simulation.
    • Each design cycle produces reusable computational evidence that strengthens the platform's partnership value.
    • Discovery decisions carry the same provenance whether they end up in a paper, an IND module or a partner deck.

    We've done this before

    See how we do Enterprise AI
  • Enterprise AI

    A connected instrument fleet across the 1,100 m² lab

    A program that pulls Captor's mixed-vendor instrument fleet onto one data backbone: network segmentation, protocol translation and a common record layer so proteomics, bioprocess and chemistry teams read from the same data.

    • Vendor-agnostic connectivity

      Every instrument on the same protocol

      Implement drivers and connectors for the lab's instruments — Beckman Coulter, Roche, Hamilton and others — using OPC UA and MQTT so device output reaches a common data layer regardless of vendor, with version control on the connector itself.

    • Closed connectivity for older equipment

      Legacy devices safely on the network

      Bridge air-gapped RS-232 and other older instrument interfaces onto the data backbone with a documented security gate, so legacy proteomics and bioprocess equipment takes part without weakening the lab's OT/IT separation.

    • Segmentation for a clinical-stage environment

      Zero Trust posture across the lab

      Establish the VLAN, identity and remote-access structure across the laboratory network so the lab can host external auditors, partners and remote reviewers without lifting the protections the company will need for a US listing.

    • Every team's output is one record, so partnership deliverables no longer need to be reconciled across systems.
    • Specialist scientific time moves from transcription and reconciliation back to design and interpretation.
    • The lab's security posture supports external data sharing — auditors, partners, US investor due diligence — without rework.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    GMP control software for clinical-scale CMC

    Control software, batch records and electronic signatures for the clinical-scale GMP manufacture of CT-01 drug product and the forthcoming CT-03 supply, designed to satisfy FDA and EMA inspection on the data the system itself produces.

    • Modular control for clinical-stage equipment

      Software that runs with the line, not after it

      Define the control layer for clinical-stage drug-substance and drug-product equipment using MTP (Module Type Package) so functional modules can be reused as Captor's CMC programme expands from CT-01 to CT-03 and beyond.

    • GMP batch records with audit-trail handling

      Records that survive an inspection

      Implement the batch record, electronic signature and audit-trail handling to 21 CFR Part 11, the US rule on electronic records and signatures, and to EU GMP Annex 11, so each clinical batch is reviewable from system evidence rather than reconstructed from paper.

    • Intuitive HMI for clinical operators

      Less operational risk at the line

      Design the human-machine interface to clinical-stage operator workflows so dose-form operations carry a low probability of human error, with safety logic implemented against recognised GMP standards.

    • CT-01 supply and the forthcoming CT-03 supply are produced against the same control software, so scaling from one asset to the next does not re-introduce validation work.
    • GMP inspection evidence is generated by the line, not assembled for the inspection visit.
    • Modular control software travels with the asset when CMC manufacturing for additional programmes is commissioned.

    We've done this before

    See how we do Digital CDMO
  • Agents

    AI agents for IND-enabling and partner documentation

    Narrow, reviewable agents that take the repetitive part of Captor's IND-enabling and partnership documentation: drafting document summaries from controlled records, checking submitted files against their templates before review, and locating every record a standards change affects. A named scientist signs each output.

    • Drafting from instrument and study records

      First drafts from system data

      Generate the first draft of an IND module section, a study summary or a partnership deliverable from the underlying proteomics, toxicology and bioprocess records, so the author reviews and judges rather than assembles from scratch.

    • Template and completeness checking

      Missing sections found before review

      Check a submitted document against its specific template — EMA CTA, FDA IND module, partnership deliverable — and against Captor's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Cross-reference and impact search

      Every record a change touches

      When a method, specification or study finding changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one and review queue volume is predictable.

    • Specialist time is recovered from assembly work and put back into the design and interpretation that human reviewers are best placed to do.
    • IND and partnership documentation arrives at review complete, so the queue moves at the speed of the review rather than the speed of the assembly.
    • Every drafted output is traceable to the records it came from and signed off by a named scientist.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Captor Therapeutics's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Laboratory digitization 45 → 92
Recent additions to the proteomics laboratory bring Captor ahead of many comparable discovery-stage peers, but day-to-day capture across the broader instrument fleet still relies on manual transfer, and the volume required to support Phase I readouts raises the bar.
Data interoperability across teams 38 → 88
Proteomics, bioprocess and chemistry teams each produce their own output; the present data architecture is consistent with the data-silo pattern common to a discovery-stage biotech growing into clinical-stage work.
Predictive drug-design modelling 50 → 90
Captor positions itself as a TechBio organisation and uses Optigrade in lead-optimisation, but the candidate-narrowing loop ahead of synthesis still sits largely outside a simulation layer.
Clinical trial data flow 32 → 85
Phase I of CT-01 is underway, which makes instrument lineage and GxP-compliant visualisation a near-term requirement rather than a forward plan.
GMP manufacturing control software 42 → 88
GMP product development for CT-01 is on the critical path and runs on a fragmented set of control systems, which is the obvious place to introduce control software that satisfies 21 CFR Part 11 before clinical volume scales.
Cybersecurity and compliance posture 58 → 92
Captor is positioning itself toward a US listing and active US partnerships, so OT/IT segmentation, electronic-records compliance and audit-trail integrity become baseline requirements rather than things to retrofit when an inspection is announced.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Captor Therapeutics, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].